DataMeds Registers 34.5M Shares for Resale, Warns of Up to 88% Dilution
MEDS is trading near its 52-week low of $0.823 (12% above the low).
Summary
DataMeds filed a pre-effective amendment to register 34.5 million shares for resale by holders of its May 2026 convertible notes and warrants, disclosing dilution of up to roughly 88% at a $1.00 conversion price. The company gets no proceeds from the resale.
Key Events · Financing and Capital Events · MEDS
-
34.5M Shares Registered for Resale
The prospectus covers 34,462,057 shares: 1,282,143 already issued, 21,300,295 issuable on conversion of the May 2026 Notes or the Series A Preferred Stock, 8,298,225 PIPE Warrant shares and 3,581,394 placement agent warrant shares.
-
Dilution Up to Roughly 88%
The company's own table shows existing holders falling to 12.0% ownership (88.0% dilution) at a $1.00 assumed conversion price and 7.4% (92.6% dilution) at $0.50, based on 4,515,862 shares outstanding as of September 28, 2026.
-
Variable Conversion Price Structure
The May 2026 Notes convert at the lesser of $6.00 and the prior day's closing price, floored at $1.00, so a lower stock price means more shares issued. The Series A Preferred Stock carries a 10% annual dividend added to stated value, compounding the dilution.
-
No Proceeds to the Company
DataMeds receives nothing from the resale; only cash exercise of the PIPE and PA Warrants would generate proceeds, which would go to working capital and general corporate purposes.
Analysis · MEDS · Trade & Services
This pre-effective amendment puts hard numbers on the May 2026 convertible financing: 34,462,057 shares are being registered for resale, and the company's own tables show existing holders could be diluted by roughly 88% at a $1.00 conversion price and 92.6% at $0.50. Because the notes convert at a discount to market with a $1.00 floor, a falling share price mechanically issues more shares — the classic death-spiral structure. No proceeds flow to the company from the resale; only warrant cash exercises would bring in money. Set against a going-concern warning and a recent Nasdaq equity deficiency, this is the clearest picture yet of how much of the company current shareholders stand to lose.
How filings like this one have moved
In the 30 days to Nov 11, 2026, 48.1% of the 1752 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.29%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, MEDS was trading at $0.92 on NASDAQ in the Trade & Services sector, with a market capitalization of approximately $4M. The 52-week trading range was $0.82 to $35.50. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.